Collectively, we assume that inhibition of the EGFR-HIF1a signaling pathway by EGFR-TKI administration suppressed the expression of HIF1a in the tumor, resulting in lower angiogenetic activity and leading to the lack of PTBE on imaging. This evidence concerns the gene HIF1A and neoplasm.